TheEdgeResearch
Home / Stocks / ISCNF

Isracann Biosciences Inc. (ISCNF)

OTC Healthcare Drug Manufacturers - Specialty & Generic
$0.00 ▲ +0.00%
Market Cap
$1,760
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
0.19
52-Wk Range
0.00001-0.0001
CEO
Ajay Singh Kaila
Country
CA
Currency
USD

Isracann Biosciences Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Vancouver, BC, CA. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $1,760. On trailing twelve-month figures it carries a trailing P/E of -0.47, a net margin of 0.0%. Its beta of 0.19 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-0.47
Price / Sales
0.00
Price / Book
7.55
EV / EBITDA
-0.97
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
Debt / equity
0.00
Current ratio
0.38
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
0
IPO date
2017-12-15
Headquarters
Vancouver, BC, CA
About Isracann Biosciences Inc.

Isracann Biosciences Inc., operating with its subsidiary companies, focuses on the growth and supply of medical-grade cannabis throughout Israel. The firm also dedicates resources to establishing new cultivation infrastructure. Additionally, it ships its products internationally to Germany. The company rebranded to Isracann Biosciences Inc. in October 2019, having previously been known as Atlas Blockchain Group Inc. Founded in 2010, its corporate headquarters are situated in Vancouver, Canada.

Comparable companies

Isracann Biosciences Inc. is most often compared with the following Healthcare names:

AVCNFCAAOFCHOOFCWBHFEVRRFGBLPMEDIFMRESRAPHVYYRF
More research on ISCNF
ISCNF technical analysis ISCNF TheEdge Score Compare against peers
Open full interactive analysis & DCF →